AKT1 and Proteus syndrome: To determine the effects of AKT inhibition specifically on SHP2Y279C/+ -associated hypertrophy, we isolated whole hearts from 16-week old SHP2Y279C/+ and SHP2+/+ mice that were treated for 4 weeks (starting at 12 weeks of age) with either vehicle or ARQ 092 (100mg/kg/day), which is in clinical trials for patients with PI3K/AKT-driven tumors or Proteus syndrome [13].